Ultime notizie per Masterbeef (NASDAQ:MB) Azioni

Masterbeef Group is a full-service restaurant group in Hong Kong, specializing in Taiwanese hotpot and Taiwanese barbecue. It operates nearly 12 restaurant outlets under Master Beef and Anping Grill brands It operate under single operating segment that is catering service.

MINDBODY

Masterbeef Group

M3-BRIGADE ACQUISITION II CORP. CL A COM

MEDBRIGHT AI INVTS INC by MEDBRIGHT AI INVTS INC.

MedBright AI Investments Inc

mBank SA

M3-Brigade Acquisition V Corp. - Class A Ordinary shares

M3-Brigade Acquisition V Corp

MEDIABAY INC by MediaBay, Inc.

iShares MBS ETF

VanEck Moody's Analytics BBB Corporate Bond ETF

Marathon Bancorp Inc

MasterBrand Inc

Monarch Blue Chips Core Index ETF

Itafos Inc

MabCure Inc

Middlefield Banc Corp

MARVEL BIOSCIENCES CORP by MARVEL BIOSCIENCES CORP.

Marvel Biosciences Corp

MASSACHUSETTS BUS DEV CRP by Massachusetts Business Development Corp.

Massachusetts Business Development Corp

MITSUBISHI UFJ FINCL GRP by Mitsubishi UFJ Financial Group, Inc.

Mitsubishi UFJ Financial Group Inc

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

Mercedes-Benz Group AG

MITSUBISHI GAS CHEM CO LT by Mitsubishi Gas Chemical Co. Inc.

Mitsubishi Gas Chemical Co Inc

MITSUBOSHI BELTING LTD by Mitsuboshi Belting Ltd

Mitsuboshi Belting Ltd

MBG Holdings Inc

MANY BRIGHT IDEAS TECH by MANY BRIGHT IDEAS TECHNOLOGIES INC.

Many Bright Ideas Technologies Inc

Moberg Pharma AB

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBH CORPORATION PLC NEW by MBH Corporation PLC

MBH Corp PLC

MASCHINENFABRIK BRTHLD PD by MASCHINENFABRIK BERTHOLD HERMLE AG

MBIA Inc

MOBILE INFRASTRUCTURE CP by MOBILE INFRASTRUCTURE CORP.

Merchants Bancorp

Merchants Bancorp - Depositary Shares, Each Representing a 1/40th Interest in a Share of 7.625% Fixed Rate Series E Non-Cumulative Perpetual Preferred Stock, without par value

Merchants Bancorp - Depositary Shares, Each Representing a 1/40th Interest in a Share of 8.25% Fixed-Rate Reset Series D Non-Cumulative Perpetual Preferred Stock

Merchants Bancorp - Depositary Shares 6.00% Fixed Rate Series C Non-Cumulative Perpetual Preferred Stock

Merchants Bancorp Depositary Shares, each representing a 1/40th interest in a share of Ser B Pref St

Mustang Bio Inc

ORANGE BELGIUM SA by Orange Belgium

METAL BANK LTD by METAL BANK LTD, SYDNEY NSW

Metal Bank Ltd

MBT BANCSHARES INC by MBT Bancshares, Inc.

MBT Bancshares Inc

MovieBloc

MOBILUM TECHNOLOGIES INC by MOBILUM TECHNOLOGIES INC.

Mobilum Technologies Inc

MORRIS ST BANCSHARES INC by Morris State Bancshares, Inc.

Morris State Bancshares Inc

Mobiventures Inc

Mobileye Global Inc. - Class A Common Stock

Mobileye Global Inc

Mobilian Coin

SPDR Nuveen Municipal Bond ETF

SPDR Series Trust SPDR Nuveen Municipal Bond ESG ETF

Metro Bank Holdings PLC

Medallion Bank - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series F

Medallion Bank

MEDALLION BANK PERP PFD G by Medallion Bank

MARINE BANCORP FLA INC by Marine Bancorp of Florida, Inc.

Marine Bancorp FLA Inc

Microbot Medical Inc

Freedom Day Dividend ETF

MOBOX

MITCHELLS & BUTLERS ORD by Mitchells & Butlers Plc

Mitchells & Butlers PLC

MITCHELLS & BTLRS UNS/ADR by Mitchells & Butlers Plc

MACBEE PLANET INC by MACBEE PLANET INC.

Mo-BRUK SA

Moleculin Biotech Inc

Angel Oak Mortgage-Backed Securities ETF

FlexShares Trust FlexShares Disciplined Duration MBS Index Fund

Valued Advisers Trust Regan Floating Rate MBS ETF

ORANGE BELGIUM UNSP/ADR by Orange Belgium

Orange Belgium SA

Advisor Managed Portfolios Regan Fixed Rate MBS ETF

Nocturne Acquisition Corp

NOCTURNE ACQUISITION CORP USD RTS

Nocturne Acquisition Corp Units (1 Ordinary Shares & 1 Rights)

MOBOTIX AG ORD by Mobotix AG, Kaiserslautern

MABUCHI MOTOR CO LTD by Mabuchi Motor Co., Ltd.

Mabuchi Motor Co Ltd

MABUCHI MOTOR CO UNSP/ADR by Mabuchi Motor Co., Ltd.

Malibu Boats Inc

MILLENNIUM BNKSHS CORP by Millennium Bankshares Corp.

Millennium Bankshares Corp

Mercantile Bank Corporation - Common Stock

Mercantile Bank Corp

MBX Biosciences Inc

MICROBIX BIOSYSTEMS INC by Microbix Biosystems Inc.

Microbix Biosystems Inc

MTB Metals Corp

Mirrored Alibaba

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">bolstering its collaborations</a> with Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and original design manufacturers (ODMs) in Taiwan.
Qualcomm has historically been a leading customer of Taiwan Semiconductor and will continue to be, as the Taipei Times <a target="_blank" href="https://www.taipeitimes.com/News/biz/archives/2025/05/20/2003837162" rel="noreferrer noopener">reported</a> on Tuesday, citing Qualcomm chief Cristiano Amon ahead of the annual Computex trade show.
Amon told the Taipei Times that Qualcomm was a leading fabless semiconductor designer.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a>
The company ships about 40 billion mobile and AI-enabled chipsets annually, and Taiwan Semiconductor is its primary manufacturing partner.
Amon highlighted Taiwan&#8217;s strength in the personal computer (PC) ecosystem and Qualcomm&#8217;s growing ties with Taiwan&#8217;s PC sector through collaboration with domestic players like Quanta Computer Inc. and Compal Electronics Inc.
Taiwan&#8217;s chip designer MediaTek will also start using Taiwan Semiconductor&#8217;s latest 2-nm chipmaking technology by September 2025, Nikkei Asia <a target="_blank" href="https://asia.nikkei.com/Business/Tech/Semiconductors/MediaTek-to-use-TSMC-s-2-nm-chip-tech-to-stay-in-AI-race2" rel="noreferrer noopener">reported</a> on Tuesday, citing MediaTek CEO Rick Tsai at Computex.
Tsai said the technology will serve its high-volume devices.
Taiwan Semiconductor is a leading contract chipmaker for companies like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). The stock has surged over 26% in the last 12 months thanks to the AI frenzy. However, the stock has dropped over 4% year-to-date as the Trump administration&#8217;s tariff policies have taken a toll on the stock, similar to its semiconductor peers.
Recently, Taiwan Minister of Economic Affairs J.W. Kuo said he did not expect the U.S. tariffs to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45508534/taiwan-minister-shrugs-off-us-tariffs-says-taiwan-semiconductor-will-thrive-while-samsung-takes-the-hit" rel="noreferrer noopener">affect Taiwanese manufacturers</a>, thanks to its semiconductor ecosystem. Kuo expects&nbsp;Taiwan Semiconductor to maintain its moat over the next decade, citing that any tariff upsurge would primarily affect U.S. customers instead of the foundry.
Price Action:&nbsp;TSM stock is down 0.87% to $191.82 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45496055/intels-next-gen-ai-tech-steals-the-show-at-computex-2025" target="_blank" rel="noreferrer noopener">Intel&#8217;s Next-Gen AI Tech Steals The Show At Computex 2025</a></li>
</ul>
Photo by wakamatsu via Shutterstock

News

Tech

Media

AAPL

NVDA

QCOM

Taiwan Semiconductor, Qualcomm, MediaTek Team Up To Power Next-Gen Mobile And AI Chips

On May 20, 2025, Union Bankshares, Inc. (the "Company") and its wholly-owned subsidiary, Union Bank (the "Bank"), entered into an Equity Distribution Agreement (the "Agreement") with Piper Sandler &amp; Co. as sales agent (the "Agent"), pursuant to which the Company may sell from time to time through the Agent, shares of the Company's common stock, par value $2.00 (the "Common Stock"), having an aggregate gross sale price of up to $40,000,000 (the "Offering"). Sales of Common Stock, if any, under the Agreement may be made in any transactions that are deemed to be "at the market offerings" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). In addition, with our prior consent and subject to the terms we may establish, the Agent may also sell the Common Stock by any other method permitted by law, including privately negotiated transactions.
Under the Agreement, the Company will set the parameters for the sale of the Common Stock from time to time, including the number of shares to be issued, the time period during which sales are requested to be made, limitations on the number of shares that may be sold by the Agent in any one trading day and any minimum price below which sales may not be made. The Company has agreed to pay the Agent a commission equal to 3% of the gross sales price of the Common Stock sold in the Offering. The Agent has agreed to use its commercially reasonable efforts to sell the shares of common stock in the Offering, subject to the terms of the Agreement.
The Agreement contains customary representations, warranties and covenants of the Company and the Bank, and conditions to the Agent's obligations to sell the Common Stock in the Offering. The Company and the Bank have agreed jointly and severally to provide to the Agent customary indemnification and contribution rights. The Company will also reimburse the Agent for certain specified expenses in connection with establishing and maintaining the Offering.
The Company has no obligation to sell any Common Stock under the Agreement, and may at any time suspend solicitation and sales in the Offering. The Agreement may be terminated at any time, for any reason, by either the Company or the Agent upon prior notice to the other party.

Offerings

Union Bankshares Enters $40M At-the-Market Equity Distribution Agreement With Piper Sandler For Potential Common Stock Sales

<ul>
<li>Red Hat OpenShift generally available on Oracle Cloud Infrastructure (OCI)</li>
<li>Oracle Cloud Infrastructure adds Red Hat OpenShift support for Dedicated Regions and Oracle Government Cloud Regions and OpenShift on Compute Cloud@Customer</li>
<li>Red Hat OpenShift now compatible with many Oracle software applications</li>
</ul>
Red Hat, the world's leading provider of open source solutions, and Oracle today announced an expanded collaboration to break down barriers to hybrid cloud adoption. This latest joint effort delivers a more consistent, cloud-native foundation that is critical for next-generation workloads including AI by bringing Red Hat Enterprise Linux and Red Hat OpenShift support to more deployment options on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.oracle.com%2Fcloud%2F&amp;esheet=54257230&amp;newsitemid=20250520218168&amp;lan=en-US&amp;anchor=Oracle+Cloud+Infrastructure&amp;index=1&amp;md5=764144fcdc5688b6556332dff40e38b7">Oracle Cloud Infrastructure</a> (OCI), including government, sovereign, and distributed cloud services.

ORCL

Red Hat And Oracle Announce Expanded Collaboration To Break Down Barriers To Hybrid Cloud Adoption; Red Hat OpenShift Now Compatible With Many Oracle Software Applications

Barclays analyst Adrienne Yih maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and raises the price target from $59 to $73.

Price Target

Analyst Ratings

URBN

Barclays Maintains Overweight on Urban Outfitters, Raises Price Target to $73

WIIM

PEGA

Pegasystems shares are trading higher following announcements that the company will join the S&P Midcap 400.

JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) reported $14.11 million in sales this quarter. This is a 3.24 percent increase over sales of $13.67 million the same period last year.

Earnings

JCSE

JE Cleantech Hldgs FY24 EPS $0.00, Sales $14.11M Up From $13.67M YoY

GDS Holdings shares are trading higher after the company reported better-than-expected Q1 EPS results.

Barclays analyst Theresa Chen maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Overweight and lowers the price target from $206 to $178.

TRGP

Barclays Maintains Overweight on Targa Resources, Lowers Price Target to $178

Health Care

General

Guardant Health Launches Guardant Hereditary Cancer Test

VIPS

Vipshop Holdings shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

New all-in-one IVT kit can deliver up to 2X more mRNA and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=TriLink+BioTechnologies&amp;index=1&amp;md5=d0e424440efc37a9e9b38a277158eddb">TriLink BioTechnologies</a>&reg; (TriLink&reg;), a Maravai&reg; LifeSciences company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), is fueling the future of mRNA research &mdash; starting with a significant donation to top academic labs across the U.S. and Europe.
The donation commemorates the launch of TriLink&#39;s first&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrilinkbiotech.com%2Fcleancap-ivt-kits&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=mRNA+synthesis+kit&amp;index=2&amp;md5=10cb95d3eb0cfb8f9c96258074fbfeac">mRNA synthesis kit</a>&nbsp;featuring CleanCap&reg; capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each that can yield up to a combined 250mg of capped mRNAs, enabling and encouraging further discovery and development in the field of mRNA-based medicine.
Labs in academic institutions, such as those listed below, have gratefully accepted the kits donated by TriLink to drive progress in RNA therapeutics and build a strong future for the field.
<ul>
<li>The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI)</li>
<li>The Center of RNA Technologies and Therapeutics at UC San Diego</li>
<li>The University Medical Center Utrecht</li>
<li>The University of Oxford</li>
<li>Yale School of Medicine</li>
</ul>
The new&nbsp;in vitro&nbsp;transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink&#39;s high-performing products where users can expect up to 2X more mRNA yield and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market. The IVT kit components include:
<ul>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleancap-reagent-ag-3-ome.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanCap%26%23174%3B+AG+%283%26%238242%3B+OMe%29&amp;index=3&amp;md5=b347179ae00eb2c566bb7ffc698a0def">CleanCap&reg; AG (3&prime; OMe)</a>&nbsp;for co-transcriptional capping</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleanscribe-rna-polymerase.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScribe%26%238482%3B+RNA+Polymerase&amp;index=4&amp;md5=10f50085c672dd825897927874d4807c">CleanScribe&trade; RNA Polymerase</a>&nbsp;for dsRNA reduction</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fbrowse%2Fnucleoside-triphosphates-nucleotides&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=Nucleotides+including+N1-methylpseuouridine&amp;index=5&amp;md5=6d9fb4fe33940c3648a6d1443b2a762a">Nucleotides including N1-methylpseuouridine</a>&nbsp;for enhanced mRNA performance, and</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgo.trilinkbiotech.com%2Fcleanscript-technote&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScript%26%23174%3B+IVT&amp;index=6&amp;md5=4f9c217670825905028a1a55813f06d4">CleanScript&reg; IVT</a>&nbsp;for increased yield.</li>
</ul>
&quot;This launch brings together a powerful suite of novel IVT components that reflect TriLink&#39;s years of experience and innovation in mRNA synthesis,&quot; shared Justin Barbosa, Vice President &amp; General Manager of TriLink Discovery. &quot;By offering all these components in a single kit, we&#39;re simplifying researcher workflow and accelerating discovery. The addition of CleanScript IVT optimization also ensures our customers can generate more high-quality mRNA per reaction &mdash; maximizing both efficiency and performance.&quot;
The kit comes ready to use and is the only commercially available IVT kit featuring CleanCap AG (3&prime; OMe), which is a modified version of the original CleanCap AG with over&nbsp;95%&nbsp;capping efficiency to improve protein expression. CleanCap co-transcriptional capping provides advantages over legacy capping methods of ARCA or enzymatic by streamlining mRNA manufacturing with fewer steps and handling, thereby saving researchers time and resources.
&quot;This is an important product launch, where we are bringing several technology and process improvements to an integrated IVT kit,&quot; said Trey Martin, CEO of Maravai. &quot;Today we are also making a statement about our commitment to the future of mRNA science. By donating the first new kits to top academic institutions across the U.S. and Europe, we are investing in the next generation of mRNA innovators and empowering groundbreaking research that could lead to the therapies of tomorrow. We are honored to help our field continue to evolve and improve through new innovations and process improvements.&quot;

MRVI

Trilink Biotechnologies Releases Its First mRNA Synthesis Kit With CleanCap Capping Technology

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity
- Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026
- Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, provides an overview of the clinical development program for its highly-differentiated antibody-drug conjugate (ADC), ALX2004, at the Company's R&amp;D webcast event today. ALX Oncology leadership will discuss the unique design profile, preclinical data and clinical development plans for ALX2004, a potential best- and first-in-class ADC for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors, that is planned to enter Phase 1 studies in mid-year 2025.

Biotech

ALXO

ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast And Colorectal Cancer Trials Also Starting Mid-2025

QBTS

D-Wave Quantum shares are trading higher after the company announced it launched its Advantage2 quantum system to address problems in optimization, AI, and materials simulation.

Management

DUOT

Duos Technologies Appoints Craig Nixon As Board Chairman

Enveric files provisional patent application on newly identified group of molecules
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com%2F&amp;esheet=54257417&amp;newsitemid=20250520560158&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=37b64f3d388bee9bd58bcc72888a61c7">Enveric Biosciences</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confirmed through further testing, the potential of this newly identified group of molecules expands the market potential for Enveric drug candidates in a new direction.
Neurodegenerative diseases are a heterogenous group of progressive neurological disorders characterized by the gradual loss of neurons, leading to a decline in cognitive, motor and other neurological functions. It has been estimated by the World Health Organization (WHO) that approximately 50 million people worldwide are affected by neurodegenerative diseases, with seven million in the United States.
Broad claims in the patent application describe a group of molecules that enhance brain derived neurotrophic factor ("BDNF") activity and address conditions where the BDNF/TrKB pathway plays a major role. BDNF and its receptor TrKB support neuroprotection and adult neurogenesis and enhance myelination by increasing the density of oligodendrocyte progenitor cells. While additional pre-clinical testing is needed to confirm the enhancement of BDNF activation, preliminary studies have revealed promotion of neuronal development in a cell-based assay.
The preliminary PK profile suggests that the orally delivered compound effectively enters the bloodstream, penetrates the brain, and is subsequently and rapidly cleared from plasma. Further, this molecule did not display 5HT2B receptor activation, which would have been an indicator of cardiovascular risk potential.

ENVB

Enveric Biosciences Files New Provisional Patent Application With Claims To Methods, Pharmaceutical Formulations For Use On Family Of Molecules Discovered To Offer Potential To Address Neurodegenerative Disease

Guidance

TRNR

Interactive Strength Updates Investor Presentation To Reflect Over $20M In Pro Forma Revenue And 15% Increase In 2025 Pro Forma Revenue Guidance To $75M+

Barclays analyst Matthew Bouley maintains Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a Equal-Weight and raises the price target from $6 to $11.

LSEA

Barclays Maintains Equal-Weight on Landsea Homes, Raises Price Target to $11

NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)), NXPLW) (&quot;NextPlat&quot; or the &quot;Company&quot;), a global e-Commerce provider, today announced that its subsidiary,&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431226-1&amp;h=3979826504&amp;u=https%3A%2F%2Fgtc.co.uk%2F&amp;a=Global+Telesat+Communications+Ltd" target="_blank">Global Telesat Communications Ltd</a>&nbsp;(&quot;GTC&quot;) has been named the exclusive UK and European Economic Area distributor for<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431226-1&amp;h=841107999&amp;u=https%3A%2F%2Fwww.zoleo.com%2Fen-us&amp;a=+ZOLEO+Inc.+(%22ZOLEO%22)%2C+an+innovative+brand+leader+in+the+satellite+communicator+segment" target="_blank">&nbsp;ZOLEO Inc. (&quot;ZOLEO&quot;), an innovative brand leader in the satellite communicator segment</a>.
ZOLEO&#39;s flagship product, the award-winning ZOLEO global satellite communicator, extends smartphone messaging coverage worldwide by utilizing the Iridium&reg;&nbsp;satellite network, cellular, and Wi-Fi networks. This device enables users to send and receive messages, access weather forecasts, and trigger SOS alerts with 24/7 monitoring, making it particularly valuable for outdoor enthusiasts, remote workers, and travelers. Notably, ZOLEO has received several industry accolades, including being named as the Outdoor Retailer Innovation Award &quot;Product of the Year.&quot; ZOLEO satellite communicators complement GTC&#39;s growing portfolio of satellite connectivity products currently sold globally via its e-commerce and Amazon storefronts.

Contracts

NXPL

NextPlat's Global Telesat Named Exclusive UK And EU Distributor For ZOLEO Satellite Communicators

Barclays analyst Paul Kearney maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Overweight and raises the price target from $75 to $86.

Barclays Maintains Overweight on Kontoor Brands, Raises Price Target to $86

<h3>Gainers</h3>
<ul>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares rose 155.4% to $0.26 during Tuesday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) stock rose 8.34% to $13.38. The company's market cap stands at $469.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock moved upwards by 7.33% to $0.64. The company's market cap stands at $16.7 million. </li>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares increased by 6.01% to $0.64. The company's market cap stands at $16.4 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Gaxos.AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) stock moved upwards by 5.87% to $1.31. The company's market cap stands at $9.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares increased by 5.84% to $3.08. The company's market cap stands at $62.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) shares declined by 9.1% to $7.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Token Cat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) stock decreased by 7.64% to $0.71. The market value of their outstanding shares is at $2.2 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares declined by 5.27% to $1.26. The company's market cap stands at $21.6 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares fell 4.54% to $0.58. The company's market cap stands at $5.7 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock declined by 4.46% to $2.36. The market value of their outstanding shares is at $3.6 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) stock fell 4.3% to $0.76. The market value of their outstanding shares is at $7.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Masterbeef

Notizie

Ultime notizie per Masterbeef (NASDAQ:MB) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO